Early Molecular Detection Technique Coupled With Urinary Test of Infectious Agents Responsible of Children CAP (OptiPAC)
Impact on Anti-infectious Treatments of the Early Molecular Detection Technique Coupled With Urinary Test of Infectious Agents Responsible of Community-acquired Pneumonia of Children at Pediatric Emergencies
Sponsor: BioMérieux
A NA clinical study on Community-Acquired Pneumonia, this trial is completed. The trial is conducted by BioMérieux and has accumulated 13 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Aug 2025 — Sep 2025 [monthly]
Completed NA
-
Sep 2024 — Aug 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
▶ Show 8 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Aug 2019 — Feb 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Aug 2019 [monthly]
Recruiting NA
-
Aug 2018 — Sep 2018 [monthly]
Recruiting NA
-
Jun 2018 — Aug 2018 [monthly]
Recruiting NA
-
Nov 2017 — Jun 2018 [monthly]
Recruiting NA
-
Sep 2017 — Nov 2017 [monthly]
Recruiting NA
-
Jan 2017 — Sep 2017 [monthly]
Recruiting NA
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioMérieux
- Centre Hospitalier Universitaire de Saint Etienne
For direct contact, visit the study record on ClinicalTrials.gov .